WO1999062539A1 - Lysine containing peptides for treatment of heart disease - Google Patents

Lysine containing peptides for treatment of heart disease Download PDF

Info

Publication number
WO1999062539A1
WO1999062539A1 PCT/EP1999/003731 EP9903731W WO9962539A1 WO 1999062539 A1 WO1999062539 A1 WO 1999062539A1 EP 9903731 W EP9903731 W EP 9903731W WO 9962539 A1 WO9962539 A1 WO 9962539A1
Authority
WO
WIPO (PCT)
Prior art keywords
mrp
lys
trp
phe
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1999/003731
Other languages
English (en)
French (fr)
Inventor
Romano Deghenghi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AT99926472T priority Critical patent/ATE314083T1/de
Priority to JP2000551795A priority patent/JP2002516872A/ja
Priority to AU43717/99A priority patent/AU4371799A/en
Priority to DE69929188T priority patent/DE69929188T2/de
Priority to HK01106504.5A priority patent/HK1035863B/en
Priority to EP99926472A priority patent/EP1082128B1/en
Priority to CA002330567A priority patent/CA2330567A1/en
Publication of WO1999062539A1 publication Critical patent/WO1999062539A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to the use of a number of different lysine containing peptides for administration to a mammal to normalize cardiac pressure for treatment of heart disease conditions such as myocardial ischemia.
  • These peptides include certain known peptides, some of which are capable of liberating growth hormone to various degrees when administered to a mammal.
  • Other peptides useful in the invention are novel peptide sequences which include a spirolactam, bicyclic or tricyclic peptidomimetic unit.
  • the peptides disclosed herein exhibit binding to cardiac tissue and have been found to normalize cardiac pressure after administration, thus imparting cardiac protecting activity by a mechanism which at the present is unknown.
  • One common feature for all peptides which are useful in this invention is that at least one lysine unit is present.
  • Mrp is 2-Alkyl-Trp, where the Alkyl group has one to three carbon atoms, IMA is imidazolylacetyl, GAB is ⁇ - amino butyryl, INIP is isonipecotinyl, AIB is amino isobutyryl,
  • R 1 is H or Tyr
  • R 2 represents the side chain of any one naturally occurring amino acid, and the configuration at * is (R) , (S) or a mixture thereof; a tricyclic compound of the formula:
  • peptides are typically administered to mammals experiencing heart diseases where cardiac pressure has been reduced. Reduced cardiac pressure is encountered after infarctions, for example, as well as in other heart problems or conditions. These peptides work directly on the heart to cause cardiac pressure to be returned to substantially normal levels.
  • the type of formulation of medicaments containing these peptides can be selected so that these peptides are rapidly delivered, e.g., by a nasal or intravenous route, when necessary.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PCT/EP1999/003731 1998-06-03 1999-05-28 Lysine containing peptides for treatment of heart disease Ceased WO1999062539A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AT99926472T ATE314083T1 (de) 1998-06-03 1999-05-28 Lysin enthaltende peptide zur behandlung von herzkrankheiten
JP2000551795A JP2002516872A (ja) 1998-06-03 1999-05-28 心疾患の治療のためのリシン含有ペプチド
AU43717/99A AU4371799A (en) 1998-06-03 1999-05-28 Lysine containing peptides for treatment of heart disease
DE69929188T DE69929188T2 (de) 1998-06-03 1999-05-28 Lysin enthaltende peptide zur behandlung von herzkrankheiten
HK01106504.5A HK1035863B (en) 1998-06-03 1999-05-28 Lysine containing peptides for treatment of heart disease
EP99926472A EP1082128B1 (en) 1998-06-03 1999-05-28 Lysine containing peptides for treatment of heart disease
CA002330567A CA2330567A1 (en) 1998-06-03 1999-05-28 Lysine containing peptides for treatment of heart disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/089,955 US5932548A (en) 1998-06-03 1998-06-03 Lysine containing peptides for treatment of heart disease
US09/089,955 1998-06-03

Publications (1)

Publication Number Publication Date
WO1999062539A1 true WO1999062539A1 (en) 1999-12-09

Family

ID=22220375

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/003731 Ceased WO1999062539A1 (en) 1998-06-03 1999-05-28 Lysine containing peptides for treatment of heart disease

Country Status (11)

Country Link
US (1) US5932548A (enExample)
EP (2) EP1616571A3 (enExample)
JP (1) JP2002516872A (enExample)
AT (1) ATE314083T1 (enExample)
AU (1) AU4371799A (enExample)
CA (1) CA2330567A1 (enExample)
DE (1) DE69929188T2 (enExample)
DK (1) DK1082128T3 (enExample)
ES (1) ES2259834T3 (enExample)
PT (1) PT1082128E (enExample)
WO (1) WO1999062539A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1297838A4 (en) * 2000-05-29 2003-07-09 Kaken Pharma Co Ltd PRALMORELIN-CONTAINED NOSE DROP PREPARATIONS
WO2007093820A1 (en) 2006-02-18 2007-08-23 Ardana Bioscience Limited Methods and kits to diagnose growth hormone deficiency
US7442778B2 (en) 2004-09-24 2008-10-28 Amgen Inc. Modified Fc molecules
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
EP2594287A1 (en) 2006-04-21 2013-05-22 Amgen Inc. Lyophilized therapeutic peptibody formulations
US9114175B2 (en) 2005-08-12 2015-08-25 Amgen Inc. Modified Fc molecules
US9145450B2 (en) 1998-10-23 2015-09-29 Amgen Inc. Thrombopoietic compounds

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US20030130185A1 (en) * 2000-09-29 2003-07-10 David Bar-Or Metal-binding compounds and uses therefor
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US6211156B1 (en) * 1999-11-10 2001-04-03 Asta Medica A.G. Peptides for treatment of erectile dysfunction
EP1297839A4 (en) * 2000-06-23 2005-12-07 Kaken Pharma Co Ltd PREVENTIVA OR THERAPEUTIC AGAINST HEART FAILURE
AU2002354951A1 (en) * 2001-07-19 2003-03-03 Dmi Biosciences, Inc. Use of copper chelators to inhibit the inactivation of protein c
TWI331922B (en) * 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
US20050002876A1 (en) * 2003-05-07 2005-01-06 Yukl Richard L. Oral care methods and products
US8536120B2 (en) * 2006-04-28 2013-09-17 The Administrators Of The Tulane Educational Fund Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof
TW200916113A (en) * 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
GB2454549B (en) * 2007-09-25 2009-09-23 Medical & Pharm Ind Tech & Dev Uses of 2-[piperidinyl]methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one for providing an anti-allergic effect and histamine H1 receptor antagonism effect
US8476408B2 (en) * 2008-06-13 2013-07-02 Alize Pharma Sas Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
EP2898900B1 (en) 2008-09-19 2017-11-15 Nektar Therapeutics Polymer conjugates of ziconotide
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
RU2404793C1 (ru) 2009-06-04 2010-11-27 Общество с ограниченной ответственностью Био Пептид Стимулятор половой, сексуальной и репродуктивной функции
RU2507212C3 (ru) 2012-03-28 2022-05-04 Общество С Ограниченной Ответственностью "Айвикс" Способ получения рекомбинантного пептида и полученный пептид
RU2626002C1 (ru) 2016-10-24 2017-07-21 Общество С Ограниченной Ответственностью "Айвикс" Новая группа пептидов для лечения женской сексуальной дисфункции

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997022620A1 (en) * 1995-12-20 1997-06-26 Romano Deghenghi Oligopeptide compounds containing d-2-alkyltryptophan capable of promoting the release of growth hormone
WO1998022124A1 (en) * 1996-11-22 1998-05-28 Pharmacia & Upjohn Ab Use of growth hormone secretagogue compound for treating cardiac failure or related vascular dysfunction
EP0898963A2 (en) * 1997-08-19 1999-03-03 Eli Lilly And Company Congestive heart failure treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668254A (en) * 1990-05-11 1997-09-16 Romano Deghenghi D-2-alkyl-tryptophan and peptides containing same
US5661122A (en) * 1994-04-15 1997-08-26 Genentech, Inc. Treatment of congestive heart failure
DK0783521T3 (da) * 1994-09-27 2003-01-27 Ardana Bioscience Ltd Polypeptidforbindelser indeholdende D-2-alkyltryptophan, hvilke er i stand til at fremme frigivelsen af væksthormon
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US5798102A (en) * 1997-03-04 1998-08-25 Milkhaus Laboratory, Inc. Treatment of cardiomyopathy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997022620A1 (en) * 1995-12-20 1997-06-26 Romano Deghenghi Oligopeptide compounds containing d-2-alkyltryptophan capable of promoting the release of growth hormone
WO1998022124A1 (en) * 1996-11-22 1998-05-28 Pharmacia & Upjohn Ab Use of growth hormone secretagogue compound for treating cardiac failure or related vascular dysfunction
EP0898963A2 (en) * 1997-08-19 1999-03-03 Eli Lilly And Company Congestive heart failure treatment

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DEGHENGHI ET AL: "The development of 'impervious peptides' as growth hormone secretagogues", ACTA PAEDIATRICA. SUPPLEMENT, vol. 423, November 1997 (1997-11-01), pages 85 - 87, XP002118402 *
LIHU Y ET AL: "Potent 3-spiropiperidine growth hormone secretagogues", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 8, no. 1-6, 6 January 1998 (1998-01-06), pages 107-112, XP004136632, ISSN: 0960-894X *
R. DEGHENGHI ET AL.: "GH-releasing activity of hexarelin, a new growth hormon releasing peptide, in infant and adult rats", LIFE SCIENCES, vol. 54, no. 18, 1994, pages 1321 - 1328, XP002118642 *
R. DEGHENGHI: "Structural requirements of growth hormone secretagogues", GROWTH HORM. SECRETAGOGUES CLIN. PRACT. INT SYMP GH SECRETAGOGUES. 2ND, 1997, pages 27 - 35, XP002118401 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145450B2 (en) 1998-10-23 2015-09-29 Amgen Inc. Thrombopoietic compounds
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US9534032B2 (en) 1998-10-23 2017-01-03 Amgen Inc. Thrombopoietic compounds
US7008927B2 (en) 2000-05-29 2006-03-07 Kaken Pharmaceutical Co., Ltd. Pralmorelin-containing nasal drop preparations
EP1297838A4 (en) * 2000-05-29 2003-07-09 Kaken Pharma Co Ltd PRALMORELIN-CONTAINED NOSE DROP PREPARATIONS
US7442778B2 (en) 2004-09-24 2008-10-28 Amgen Inc. Modified Fc molecules
US9114175B2 (en) 2005-08-12 2015-08-25 Amgen Inc. Modified Fc molecules
US11266744B2 (en) 2005-08-12 2022-03-08 Amgen Inc. Modified Fc molecules
US10188740B2 (en) 2005-08-12 2019-01-29 Amgen Inc. Modified Fc molecules
WO2007093820A1 (en) 2006-02-18 2007-08-23 Ardana Bioscience Limited Methods and kits to diagnose growth hormone deficiency
US8192719B2 (en) 2006-02-18 2012-06-05 Aeterna Zentaris Gmbh Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds
EP2594288A1 (en) 2006-04-21 2013-05-22 Amgen Inc. Lyophilized therapeutic peptibody formulations
EP2594286A1 (en) 2006-04-21 2013-05-22 Amgen Inc. Lyophilized therapeutic peptibody formulations
EP2594284A1 (en) 2006-04-21 2013-05-22 Amgen Inc. Lyophilized therapeutic peptibody formulations
EP2594285A1 (en) 2006-04-21 2013-05-22 Amgen Inc. Lyophilized therapeutic peptibody formulations
EP2594287A1 (en) 2006-04-21 2013-05-22 Amgen Inc. Lyophilized therapeutic peptibody formulations

Also Published As

Publication number Publication date
AU4371799A (en) 1999-12-20
JP2002516872A (ja) 2002-06-11
EP1616571A2 (en) 2006-01-18
DE69929188T2 (de) 2006-08-17
EP1082128A1 (en) 2001-03-14
ATE314083T1 (de) 2006-01-15
DK1082128T3 (da) 2006-04-10
PT1082128E (pt) 2006-05-31
CA2330567A1 (en) 1999-12-09
HK1035863A1 (en) 2001-12-14
US5932548A (en) 1999-08-03
EP1082128B1 (en) 2005-12-28
ES2259834T3 (es) 2006-10-16
EP1616571A3 (en) 2008-08-13
DE69929188D1 (de) 2006-02-02

Similar Documents

Publication Publication Date Title
US5932548A (en) Lysine containing peptides for treatment of heart disease
US6025471A (en) Diazaspiro, azepino and azabicyclo therapeutic peptides
US4410512A (en) Combinations having synergistic pituitary growth hormone releasing activity
TWI331922B (en) Growth hormone releasing peptides
CN102821775B (zh) 生长激素促分泌素受体配体的药物组合物
US6124263A (en) Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
US4504414A (en) Synthetic pyridyl-alanyl decapeptides having antiovulatory activity
KR100369104B1 (ko) 성장호르몬의유리를촉진하는2-알킬트립토판함유-올리고펩티드화합물
KR0123009B1 (ko) 쥐이엔알에이취(GnRH) 유사체
US5795957A (en) Polypeptide compounds containing D-2-alkyltryptophan capable of promoting the release of growth hormone
US7034050B2 (en) Pseudopeptides growth hormone secretagogues
US5962409A (en) Somatostatin-analogous cyclic peptides with inhibitory activity on growth hormone
Janecka et al. Reduced-size antagonists of luteinizing hormone-releasing hormone active in vitro
Sakura et al. Structure-activity relationships of neuromedin U. IV. Absolute requirement of the arginine residue at position 7 of dog neuromedin U-8 for contractile activity
HK1083068A (en) Lysine containing peptides for treatment of heart disease
HK1035863B (en) Lysine containing peptides for treatment of heart disease
AU768516B2 (en) Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
EP1756142B1 (en) Pseudopeptides growth hormone secretagogues
HK1102373B (en) Pseudopeptides growth hormone secretagogues
HK1008225B (en) Somatostatin-analogous cyclic peptides with inhibitory activity on growth hormone

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999926472

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2330567

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1999926472

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 1999926472

Country of ref document: EP